DOCSLIB.ORG

2020 Research Annual Report Table of Contents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2020 Research Annual Report Table of Contents 2020 RESEARCH ANNUAL REPORT TABLE OF CONTENTS PART I – INTERNAL MEDICINE DEPARTMENT ALLERGY AND IMMUNOLOGY ...................................................................................... 1 CARDIOLOGY/CARDIOVASCULAR RESEARCH…………………………………………..2 ENDOCRINOLOGY AND METABOLISM ........................................................................ 3 GASTROENTEROLOGY ................................................................................................ 5 HYPERTENSION AND VASCULAR RESEARCH……………………………………….…...6 PULMONARY……………………………………………………………………………………10 SLEEP MEDICINE………………………………………………………………………………10 GENERAL INTERNAL MEDICINE…………………………………………………….………12 HEMATOLOGY/ONCOLOGY………………………………………………………………….12 PART II – ALL OTHER CLINICAL DEPARTMENTS DERMATOLOGY ......................................................................................................... .14 EMERGENCY MEDICINE……………………………………………………………………..17 NEUROLOGY…………………………………………………………………………………...19 NEUROSURGERY……………………………………………………………………………… ORTHOPAEDICS/BONE & JOINT…………………………………………………………….31 OTOLARYNGOLOGY………………………………………………………………………… .36 PATHOLOGY ................................................................................................................ .36 PEDIATRICS…………………………………………………………………………………….37 PSYCHIATRY/BEHAVORIAL HEALTH………………………………………………………38 RADIATION ONCOLOGY ............................................................................................. 39 UROLOGY………………………………………………………………………………………40 WOMEN’S HEALTH……………………………………………………………………………42 i PART III POPULATION SCIENCES CENTER FOR HEALTH POLICY AND HEALTH SERVICES RESEARCH………………44 CENTER FOR INDIVIDUALIZED AND GENOMIC MEDICINE…………………………...49 DEPARTMENT OF PUBLIC HEALTH SCIENCES ........................................................ 50 ii PUBLICATIONS ADMINISTRATION……………………………………………………………………………..51 ALLERGY AND IMMUNOLOGY…………………………………………………………… 51 ANESTHESIOLOGY………………………………………………………………………… 52 BEHAVIORAL HEALTH SERVICES/PSYCHIATRY/PSYCHOLOGY....................................................................54 CARDIOLOGY/CARDIOVASCULAR MEDICINE…………………………………………..56 CENTER FOR HEALTH POLICY AND HEALTH SERVICES RESEARCH………………72 CLINICAL QUALITY AND SAFETY………………………………………………………….76 DERMATOLOGY……………………………………………………………………………….76 DIAGNOSTIC RADIOLOGY…………………………………………………………………..86 EMERGENCY MEDICINE ............................................................................................. 90 ENDOCRINOLOGY……………………………………………………………………………95 GASTROENTEROLOGY……………………………………………………………………...97 GRADUATE MEDICAL EDUCATION………………………………………………………101 HEMATOLOGY/ONCOLOGY……………………………………………………………….101 HOSPITAL MEDICINE………………………………………….……………………………105 HYPERTENSION/VASCULAR RESEARCH………………………………………………105 INTERNAL MEDICINE……………………………………………………………………….111 NEPHROLOGY……………………………………………………………………………….116 NEUROLOGY…………………………………………………………………………………118 NEUROSURGERY……………………………………………………………………………127 NURSING……………………………………………………………………………………...133 OBSTETRICS, GYNECOLOGY AND WOMEN’S HEALTH SERVICES……………….134 iii OPTHALMOLOGY…………………………………..…………………………………………135 ORTHOPAEDICS/BONE & JOINT/SPORTS MEDICINE.………………………………...137 OTOLARYNGOLOGY…………………………………………………………………………142 PATHOLOGY/LABORATORY MEDICINE……………..………………………………….. 145 PHARMACY…………………………………………………………………………………… 150 PLASTIC SURGERY…………………………………………………………………………. 153 PUBLIC HEALTH SCIENCES………………………………………………………………..153 PULMONARY/CRITICAL CARE……………………………………………………………..165 RADIATION ONCOLOGY…………………………………………………………………….167 REHABILITATION SERVICES………………………………………………………………171 RESEARCH ADMINISTRATION…………………………………………………………….172 RHEUMATOLOGY……………………………………………………………………………172 SLEEP MEDICINE…………………………………………………………………………….172 SURGERY…………………………………………………………………………………… 174 UROLOGY……………………………………………………………………………………...183 iv ABSTRACTS ADMINISTRATION ......................................................................................................188 ALLERGY AND IMMUNOLOGY………………………………………………….………....188 ANESTHESIOLOGY……………………………………………………...…………………...189 BEHAVIORAL HEALTH/PSYCHIATRY…………………………………………………….189 CARDIOLOGY…………………………………………………………………………………189 CENTER FOR HEALTH POLICY….…………………………………………...……………196 CLINICAL QUALITY .................................................................................................... 197 DERMATOLOGY……………………………………………………………………………...197 DIAGNOSTIC RADIOLOGY…………………………………………………...…………….200 EMERGENCY MEDICINE…………………………………………………………………….201 ENDOCRINOLOGY/METABOLISM………………………………………………………....204 GASTROENTEROLOGY……………………………………………………………………...204 GRADUATE MEDICINE………………………………………………………………………207 HEMATOLOGY/ONCOLOGY………………………………………………………………. 207 INFECTIOUS DISEASE………………………...…………………………………………….209 INTERNAL MEDICINE…………………………………………………………….……….... 210 NEUROLOGY ............................................................................................................. 214 NEUROSURGERY ..................................................................................................... 214 NURSING…………………………………………………………………………...…….……215 OBSTETRICS, GYNECOLOGY AND WOMEN’S HEALTH SERVICES ...................... 215 OPHTHALMOLOGY/EYE CARE…………………………………………………………….216 ORTHOPAEDICS/BONE & JOINT/SPORTS MEDICINE ............................................ 216 OTOLARYNGOLOGY ................................................................................................. 217 PATHOLOGY .............................................................................................................. 217 PEDIATRICS…………………………………………………………………………………...219 v PHARMACY ................................................................................................................ 219 PLASTIC SURGERY………………………………………………………………………….220 PUBLIC HEALTH SCIENCES .................................................................................... 220 PULMONARY/CRITICAL CARE…………………………………………………………….223 RADIATION ONCOLOGY ........................................................................................... 224 SLEEP MEDICINE…………………………………………………………………………….228 SURGERY………………………………………………………………………………………228 UROLOGY………………………………………………………………………………………231 BOOKS AND CHAPTERS…………………………………………………………………….233 HFHS PUBLICATIONS ON COVID-19………………………………………………………236 vi Summaries of 2020 National Institutes of Health and other Federal Grants Awarded to HFHS Part I –Department of Internal Medicine • Allergy and Immunology • Cardiology/Cardiovascular Research • Endocrinology and Metabolism • Gastroenterology • Hypertension and Vascular Research • Infectious Disease • Pulmonary • Sleep Medicine • General Internal Medicine • Hematology/Oncology Allergy and Immunology Principal Investigator: Edward Zoratti, M.D. ICAC 3 - Inner City Asthma Consortium Infrastructure (UM1AI114271) Subcontract The objectives of the Inner-City Asthma Consortium are to implement a long-range scientific plan to reduce asthma severity and prevent asthma among inner city children and to identify the mechanisms involved in the immunopathogenesis of asthma in these populations. The specific objectives are to: 1) conduct clinical trials to evaluate the safety and efficacy of promising immune based therapies in reducing asthma severity and preventing disease onset in minority children residing in inner cities in the United States; 2) conduct research to delineate the underlying mechanisms of such therapies as an integral part of the clinical trials undertaken by the Consortium; 3) conduct clinical studies on the immunopathogenesis of asthma onset, progression and severity; and 4) develop and validate surrogate/biomarkers to measure disease stage, progression and therapeutic effect. Principal Investigator: Edward Zoratti, M.D. Project 2-Maternal Factors and their Effect on a Child's Gut Microbiota and IgE Production (P01AI089473-06) This application builds on the findings of our initial P01 designed to examine relationships between environmental factors, especially pets, the infant gut microbiota and pediatric allergic asthma. We have shown that: 1) dogs alter the microbial composition of dust in homes, 2) children born into homes with dogs have different developmental patterns of gut microbiota and of IgE, 3) a distinct pattern of gut microbial composition at 1 month of age is related to heightened risk of sensitization to multiple allergens at 2 years and of asthma at 4 years, and this pattern is influenced by numerous maternal characteristics, 4) sensitization to multiple food and inhalant allergens at 2 years is strongly related to asthma at 10 years, 5) the metabolic profiles of stools are related to later allergic sensitization 6) 12,13-DiHOME, a metabolite in stool, promotes development of Th2lymphocytes and lowers development of Treg lymphocytes in an in vitro assay, and 7) in another study, theme conial microbiota is distinct in neonates born to mothers with asthma. Our complementary mouse studies have shown that: 1) gavaging with dust from homes with dogs reduces lung inflammation from allergen sensitization and from respiratory syncytial virus (RSV) infection, 2) dog dust gavaged mice have increases Lactobacillus johnsonii in their ceca 3) oral administration of live L. johnsonii confers protection against pulmonary inflammation induced by allergen and RSV, 4) L. johnsonii alters the function of bone marrow derived dendritic cells, 5) mice orally supplemented with L. johnsonii have altered serum metabolic profiles, and 6) mouse pups born to L. johnsonii-supplemented mothers are protected against allergen challenge and RSV infection. Collectively 1 these findings showing the influence
Load more

Recommended publications
  • Acne Class Update
    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-2596 Drug Class Update with New Drug Evaluation: Acne Drugs Date of Review: June 2020 Date of Last Review: November 2018 Dates of Literature Search: 08/03/2018 - 12/26/2019 Generic Name: Trifarotene Brand Name (Manufacturer): Aklief® (Galderma Laboratories, LP) Dossier Received: no Current Status of PDL Class: See Appendix 1. Purpose for Class Update: The acne class has had one new approval, trifarotene cream, and several new product formulations since it was last reviewed in 2018. The purpose of this update is to evaluate new comparative evidence for trifarotene cream for the treatment of acne vulgaris and any new data on comparative efficacy or harms in the acne class since the previous update. Acne conglobata, acne fulminans, and severe cystic acne are covered conditions under the Oregon Health Plan (OHP). Research Questions: 1. What is the comparative efficacy and effectiveness of treatments for severe acne (topical agents of adapalene, adapalene/benzoyl peroxide, tretinoin, tazarotene, benzoyl peroxide, salicylic acid, dapsone, azelaic acid, clindamycin, erythromycin, minocycline, sulfacetamide, trifarotene; oral systemic antibiotics of doxycycline, minocycline, tetracycline, azithromycin, erythromycin, clindamycin, trimethoprim, and sulfamethoxazole/trimethoprim; hormonal agents of oral contraceptives and spironolactone; and oral isotretinoin)? 2. What are the comparative harms of treatments for severe acne? 3. Are there subpopulations of patients in which a particular treatment for severe acne would be more effective or associated with less harm? Conclusions: There are no new high-quality clinical practice guidelines which have evaluated comparative efficacy and safety of treatments for acne vulgaris.
    [Show full text]
  • DRUG and MEDICAL DEVICE HIGHLIGHTS Helping You Maintain and Improve Your Health 2019
    DRUG AND MEDICAL DEVICE HIGHLIGHTS Helping you maintain and improve your health 2019 DRUG AND MEDICAL DEVICE HIGHLIGHTS 2019 Helping you maintain and improve your health Learn about the new drugs and medical devices that Health Canada approved for sale in Canada, the information we published about potential safety issues, and our other accomplishments in 2019. Health Canada is the federal department responsible for helping the people of Canada maintain and improve their health. Health Canada is committed to improving the lives of all of Canada’s people and to making this country’s population among the healthiest in the world as measured by longevity, lifestyle and effective use of the public health care system. Également disponible en français sous le titre : Préserver et améliorer votre santé : Faits saillants sur les médicaments et les instruments médicaux 2019 To obtain additional information, please contact: Health Canada Address Locator 0900C2 Ottawa, ON K1A 0K9 Tel.: 613-957-2991 Toll free: 1-866-225-0709 Fax: 613-941-5366 TTY: 1-800-465-7735 E-mail: [email protected] © Her Majesty the Queen in Right of Canada, as represented by the Minister of Health, 2020 Publication date: May 2020 This publication may be reproduced for personal or internal use only without permission provided the source is fully acknowledged. Cat.: H161-11E-PDF ISSN: 2562-9816 Pub.: 190484 CONTENTS WELCOME TO OUR 2019 HIGHLIGHTS REPORT ..........................................................................................1 MESSAGE FROM THE CHIEF MEDICAL
    [Show full text]
  • 19F Henry Ford Health System Publication List – May 2021 This
    19f Henry Ford Health System Publication List – May 2021 This bibliography aims to recognize the scholarly activity and provide ease of access to journal articles, meeting abstracts, book chapters, books and other works published by Henry Ford Health System personnel. Searches were conducted in PubMed, Embase, and Web of Science during the month, and then imported into EndNote for formatting. There are 144 unique citations listed this month, with 8 articles and 5 conference abstracts on COVID-19. Articles are listed first, followed by conference abstracts, books and book chapters, and a bibliography of publications on COVID-19. Because of various limitations, this does not represent an exhaustive list of all published works by Henry Ford Health System authors. Click the “Full Text” link to view the articles to which Sladen Library provides access. If the full- text of the article is not available, you may request it through ILLiad by clicking on “Request Article,” or calling us at (313) 916-2550. If you would like to be added to the monthly email distribution list to automatically receive a PDF of this bibliography, or you have any questions or comments, please contact [email protected]. If your published work has been missed, please use this form to notify us for inclusion on next month’s list. All articles and abstracts listed here are deposited into Scholarly Commons, the HFHS institutional repository. Jump to: Articles Administration Neurology Allergy and Immunology Neurosurgery Anesthesiology Obstetrics, Gynecology and Women’s Behavioral
    [Show full text]
  • A20-73 Trifarotene (Acne Vulgaris) – Benefit Assessment According to §35A Social Code Book V1
    IQWiG Reports – Commission No. A20-73 Trifarotene (acne vulgaris) – Benefit assessment according to §35a Social Code Book V1 Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Trifaroten (Acne vulgaris) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 12 November 2020). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract of dossier assessment A20-73 Version 1.0 Trifarotene (acne vulgaris) 12 November 2020 Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Trifarotene (acne vulgaris) – Benefit assessment according to §35a Social Code Book V Commissioning agency Federal Joint Committee Commission awarded on 13 August 2020 Internal Commission No. A20-73 Address of publisher Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1 E-mail: [email protected] Internet: www.iqwig.de Institute for Quality and Efficiency in Health Care (IQWiG) - i - Extract of dossier assessment A20-73 Version 1.0 Trifarotene (acne vulgaris) 12 November 2020 Medical and scientific advice . Prof. Dr. med. Dr. rer. nat. Enno Schmidt, University Hospital Schleswig-Holstein, Lübeck, Germany IQWiG thanks the medical and scientific advisor for his contribution to the dossier assessment. However, the advisor was not involved in the actual preparation of the dossier assessment. The responsibility for the contents of the dossier assessment lies solely with IQWiG. IQWiG employees involved in the dossier assessment . Anke Penno . Katharina Biester . Moritz Felsch .
    [Show full text]
  • Aars Hot Topics Member Newsletter
    AARS HOT TOPICS MEMBER NEWSLETTER American Acne and Rosacea Society 201 Claremont Avenue • Montclair, NJ 07042 (888) 744-DERM (3376) • [email protected] www.acneandrosacea.org Like Our YouTube Page Visit acneandrosacea.org to Become an AARS Member and TABLE OF CONTENTS Donate Now on acneandrosacea.org/donate AARS News Register Now for the AARS 9th Annual Scientific Symposium .................................... 2 Our Officers AARS BoD Member Emmy Graber invites you to earn free CME! ............................. 3 J. Mark Jackson, MD AARS President New Medical Research The effect of 577-nm pro-yellow laser on demodex density in patients with rosacea 4 Andrea Zaenglein, MD Aspirin alleviates skin inflammation and angiogenesis in rosacea ............................. 4 AARS President-Elect Efficacy and safety of intense pulsed light using a dual-band filter ............................ 4 Split-face comparative study of fractional Er:YAG laser ............................................. 5 Joshua Zeichner, MD Evaluation of biophysical skin parameters and hair changes ..................................... 5 AARS Treasurer Dermal delivery and follicular targeting of adapalene using PAMAM dendrimers ...... 6 Therapeutic effects of a new invasive pulsed-type bipolar radiofrequency ................ 6 Bethanee Schlosser, MD Efficacy and safety of a novel water-soluble herbal patch for acne vulgaris .............. 6 AARS Secretary A clinical study evaluating the efficacy of topical bakuchiol ........................................ 7 Tolerability and efficacy of clindamycin/tretinoin versus adapalene/benzoyl peroxide7 James Del Rosso, DO Photothermal therapy using gold nanoparticles for acne in Asian patients ................ 8 Director Development of a novel freeze-dried mulberry leaf extract-based transfersome gel . 8 The efficacy and safety of dual-frequency ultrasound for improving skin hydration ... 9 Emmy Graber, MD Director Clinical Reviews Jonathan Weiss, MD What the pediatric and adolescent gynecology clinician needs to know about acne .
    [Show full text]
  • 213433Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 213433Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review NDA/BLA Multidisciplinary Review and Evaluation: NDA 213433 WINLEVI (clascoterone) cream, 1% NDA Multidisciplinary Review and Evaluation Application Type NME- In “The Program” Application Number(s) NDA 213433 Priority or Standard Standard Submit Date(s) August 19, 2019 Received Date(s) August 27, 2019 PDUFA Goal Date August 27, 2020 Division/Office Shari Targum, Deputy Director, Division of Dermatology and Dentistry Julie Beitz, Director Office of Immunology and Inflammation Review Completion Date Established/Proper Name Clascoterone cream, 1% (Proposed) Trade Name WINLEVI Pharmacologic Class NME Code Name N/A Applicant Cassiopea SpA Dosage Form Topical cream Applicant proposed Dosing Apply a thin layer (approximately 1 gram) to affected area Regimen twice daily (morning and evening) Applicant Proposed For the treatment of acne vulgaris in patients 9 years of age Indication(s)/Population(s) and older Applicant Proposed SNOMED CT Indication Disease Term for Each Proposed Indication Recommendation on Regulatory Action Approval Recommended For the treatment of acne vulgaris in patients 12 years of age Indication(s)/Population(s) and older (if applicable) Recommended SNOMED CT Indication Disease Term for Each Indication (if applicable) Recommended Dosing Apply a thin layer (approximately 1 gram) to affected area Regimen twice daily (morning and
    [Show full text]
  • Kaiser Permanente Bernard J. Tyson School of Medicine, Inc. Exclusive Provider Organization (EPO) Student Blanket Health Plan Drug Formulary
    Kaiser Permanente Bernard J. Tyson School of Medicine, Inc. Exclusive Provider Organization (EPO) Student Blanket Health Plan Drug Formulary Effective September 1, 2021 Health Plan Products: Kaiser Permanente Bernard J. Tyson School of Medicine, EPO Student Blanket Health Plan offered by Kaiser Permanente Insurance Company For the most current list of covered medications or for help understanding your KPIC insurance plan benefits, including cost sharing for drugs under the prescription drug benefit and under the medical benefit: Call 1-800-533-1833, TTY 711, Monday through Friday, 7 a.m. to 9 p.m. ET Visit kaiserpermanente.org to: • Find a participating retail pharmacy by ZIP code. • Look up possible lower-cost medication alternatives. • Compare medication pricing and options. • Find an electronic copy of the formulary here. • Get plan coverage information. For cost sharing information for the outpatient prescription drug benefits in your specific plan, please visit kp.org/kpic-websiteTBD The formulary is subject to change and all previous versions of the formulary are no longer in effect. Kaiser Permanente Last updated: September 1, 2021 Table of Contents Informational Section...........................................................................................................................................3 ANTIHISTAMINE DRUGS - Drugs for Allergy.....................................................................................................9 ANTI-INFECTIVE AGENTS - Drugs for Infections...........................................................................................
    [Show full text]
  • To Download the AARS Hot Topics Newsletter
    AARS HOT TOPICS MEMBER NEWSLETTER American Acne and Rosacea Society 201 Claremont Avenue • Montclair, NJ 07042 (888) 744-DERM (3376) • [email protected] www.acneandrosacea.org Like Our YouTube Page We encourage you to TABLE OF CONTENTS invite your colleagues and patients to get active in AARS Special Announcements th the American Acne & Register for the 14 Annual Networking Reception at AAD ............................................2 Rosacea Society! Visit AARS Grantee publication ...................................................................................................2 www.acneandrosacea.org to become member and New Medical Research donate now on Gender- and age-related differences in facial sebaceous glands in Asian skin ......... 2 www.acneandrosacea.org/ A microtube array membrane (MTAM) encapsulated live fermenting ........................ 3 donate to continue to see Tranexamic acid ameliorates rosacea symptoms ....................................................... 3 a change in acne and Treatment of acne with a combination of propolis, tea tree oil, and aloe vera ........... 3 rosacea. New study to assess treatments for antibiotic-resistant skin infections ...................... 4 Microneedling by dermapen and glycolic acid peel for the treatment of acne scars .. 4 Association of caffeine intake and caffeinated coffee consumption ........................... 5 Association between market competition and prices of generic topical ..................... 5 BPX-01 minocycline topical gel shows promise for the treatment .............................
    [Show full text]
  • Mississippi Division of Medicaid Universal Preferred Drug List
    MISSISSIPPI DIVISION OF MEDICAID EFFECTIVE 01/01/2021 UNIVERSAL PREFERRED DRUG LIST Version 2021.13a Updated: 8-30-2021 (For All Medicaid, MSCAN and CHIP Beneficiaries) Conduent’s SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid’s PA criteria. THERAPEUTIC PREFERRED AGENTS NON-PREFERRED AGENTS PA CRITERIA DRUG CLASS ACNE AGENTS ANTI-INFECTIVE clindamycin gel (generic Cleocin-T) ACZONE (dapsone) Maximum Age Limit clindamycin lotion AKNE-MYCIN (erythromycin) • 21 years – all agents except clindamycin solution azelaic acid isotretinoins AMZEEQ FOAM (minocycline) AZELEX (azelaic acid) CLEOCIN-T (clindamycin) CLINDAMYCIN PAC (clindamycin) CLINDAGEL (clindamycin) clindamycin foam clindamycin gel daily (generic Clindagel) dapsone ERY (erythromycin) ERYGEL (erythromycin) erythromycin gel, swabs, solution EVOCLIN (clindamycin) KLARON (sulfacetamide) sulfacetamide RETINOIDS RETIN-A (tretinoin) adapalene tretinoin cream AKLIEF (trifarotene) ALTRENO (tretinoin) ARAZLO (tazarotene) ATRALIN (tretinoin) AVITA (tretinoin) DIFFERIN (adapalene) FABIOR (tazarotene) PLIXDA (adapalene) 1 Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act.This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status. An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.
    [Show full text]
  • Clinical Policy: Topical Agents: Acne Preparations
    Clinical Policy: Topical Agents: Acne Preparations Reference Number: OH.PHAR.PPA.89 Effective Date: 01.20 Revision Log Last Review Date: 07.20 Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory and legal information. Description ANTIBIOTIC PRODUCTS NO PA REQUIRED “PREFERRED” PA REQUIRED “NON-PREFERRED” CLINDAMYCIN gel (generic of Cleocin T®, Clindamax®) AMZEEQ™ foam (minocycline) CLINDAMYCIN lotion (generic of Cleocin T®, Clindamax®) CLINDACIN® Pak (clindamycin/skin cleanser kit) CLINDAMYCIN solution (generic of Cleocin T®) CLINDAMYCIN foam (generic of Evoclin®) ERYTHROMYCIN gel CLINDAMYCIN pledgets (generic of Cleocin T®) ERYTHROMYCIN solution (generic of A/T/S®, Akne- ERYTHROMYCIN pads (generic of Ery Pads®) Mycin®) ACNE PREPARATIONS – OTHER PRODUCTS NO PA REQUIRED “PREFERRED” PA REQUIRED “NON-PREFERRED” AZELEX® cream (azelaic acid) ACZONE® gel (dapsone) FINACEA® gel (azelaic acid) BENZOYL PEROXIDE AND COMBINATION PRODUCTS NO PA REQUIRED “PREFERRED” PA REQUIRED “NON-PREFERRED” CLINDAMYCIN-BENZOYL PEROXIDE gel (generic of ACANYA® (clindamycin-benzoyl peroxide) Benzaclin®, Duac®) BENZOYL PEROXIDE foam (generic of Benzefoam®) BENZOYL PEROXIDE cleanser 5%, 6% & 10% ONEXTONTM gel (clindamycin-benzoyl peroxide) BENZOYL PEROXIDE gel 2.5%, 5%, 10% BPO (benzoyl peroxide) Gel 4% & 8% BENZOYL PEROXIDE wash (generic of Benzac AC ®, Benzac W®, Brevoxyl®, Desquam-X®, Pacnex®) ERYTHROMYCIN-BENZOYL PEROXIDE gel (generic of Benzamycin®) NEUAC® gel (clindamycin-benzoyl peroxide) PANOXYL® 10% foam, wash
    [Show full text]
  • 2021 Aetna Pharmacy Drug Guide
    Plan for your best health Advanced Control Plan - Aetna: Federal Employees Aetna.com Health benefits and health insurance plans are offered, administered and/or underwritten by Aetna Health Inc., Aetna Health Insurance Company of New York, Aetna HealthAssurance Pennsylvania Inc., Aetna Health Insurance Company and/or Aetna Life Insurance Company (Aetna). In Florida, by Aetna Health Inc. and/or Aetna Life Insurance Company. In Utah and Wyoming by Aetna Health of Utah Inc. and Aetna Life Insurance Company. In Maryland, by Aetna Health Inc., 151 Farmington Avenue, Hartford, CT 06156. Each insurer has sole financial responsibility for its own products. 2021 Pharmacy Drug Guide - Advanced Control Plan - Aetna: Federal Employees Table of Contents INFORMATIONAL SECTION..................................................................................................................4 ANALGESICS........................................................................................................................................... 14 ANTIDOTES AND SPECIFIC ANTAGONISTS.................................................................................... 25 ANTI-INFECTIVES..................................................................................................................................25 ANTINEOPLASTIC AGENTS................................................................................................................. 41 ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES..................................................................... 49
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]